Pancreatic Cancer Research

ResearcherUniversity Hospital Schleswig-HolsteinActive in the last 2 years

Rüdiger Braun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1662-2109; OpenAlex author ID A5060206685, A5111010015, A5146548236. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2021: 5 papers · 2022: 3 papers · 2023: 7 papers · 2024: 3 papers · 2025: 3 papers · 2026: 5 papers

Papers 26

  1. Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer. Co-author DOI 10.1016/j.biopha.2026.119257↗
  2. Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41698-026-01663-z↗
  3. Current Advances in Preclinical Patient-Derived Cultivation Models for Individualized Drug Response Prediction in Pancreatic Cancer. Last author DOI 10.32604/or.2026.075028↗
  4. Octogenarians and Pancreatic Cancer: Is Surgery Always the Right Choice? Co-author DOI 10.3390/cancers18152423↗
  5. L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the complex tumor stroma Co-author DOI 10.64898/2026.08.10.743835↗
  6. Regulation of epithelial-mesenchymal plasticity in pancreatic ductal adenocarcinoma: Role of key molecules in tumor differentiation and therapy. Co-author DOI 10.1016/j.ejca.2025.115561↗
  7. An R0 resection margin does improve overall survival after PDAC resection- real-world evidence from 6.000 cases from the German Cancer Registry Group. Co-author DOI 10.1016/j.ejso.2025.109693↗
  8. Insulin-like peptide 3 is not a biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fendo.2025.1625906↗
  9. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national re… Co-author DOI 10.1016/j.surg.2023.11.004↗
  10. RAC1b Collaborates with TAp73α-SMAD4 Signaling to Induce Biglycan Expression and Inhibit Basal and TGF-β-Driven Cell Motility in Human Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12010199↗
  11. Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic D… Co-author DOI 10.3390/cancers16112016↗
  12. Recent onset diabetes is associated with better survival in pancreatic ductal adenocarcinoma-An analysis of preoperative symptoms within the DGAV StuDoQ|Pancre… Co-author DOI 10.1016/j.surg.2023.04.042↗
  13. Overexpression of integrin alpha 2 (ITGA2) correlates with poor survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2022-208176↗
  14. Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations. Last author DOI 10.3389/fonc.2023.1230382↗
  15. Elucidation of the Role of SMAD4 in Epithelial-Mesenchymal Plasticity: Does It Help to Better Understand the Consequences of DPC4 Inactivation in the Malignant… Co-author DOI 10.3390/cancers15030581↗
  16. Preclinical Patient-Derived Culture Models for Personalized Treatment of Pancreatic Cancer: A Dream of the Future or Useful Practice? Co-author DOI 10.3390/cancers15113027↗
  17. TAp73 Inhibits EMT and Cell Migration in Pancreatic Cancer Cells through Promoting SMAD4 Expression and SMAD4-Dependent Inhibition of ERK Activation. Co-author DOI 10.3390/cancers15153791↗
  18. Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response. Co-author DOI 10.3390/cells12040587↗
  19. [Incidence, Treatment and Survival in Pancreatic Cancer- Data of the Nationwide Oncological Quality Conference from a Surgical Perspective]. Co-author DOI 10.1055/a-1768-1012↗
  20. Suppressive Role of ACVR1/ALK2 in Basal and TGFβ1-Induced Cell Migration in Pancreatic Ductal Adenocarcinoma Cells and Identification of a Self-Perpetuating Au… First author DOI 10.3390/biomedicines10102640↗
  21. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cance… Co-author DOI 10.3390/cancers14040868↗
  22. Radiological prediction of portal vein infiltration in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.015↗
  23. Postoperative Outcomes of Tangential versus Segmental Resection and End-to-end Reconstruction of the Superior Mesenterico-Portal Vein During Pancreatoduodenect… Co-author DOI 10.21873/anticanres.15329↗
  24. A Comparative Endocrine Trans-Differentiation Approach to Pancreatic Ductal Adenocarcinoma Cells with Different EMT Phenotypes Identifies Quasi-Mesenchymal Tum… Co-author DOI 10.3390/cancers13184663↗
  25. Activation of a Ductal-to-Endocrine Transdifferentiation Transcriptional Program in the Pancreatic Cancer Cell Line PANC-1 Is Controlled by RAC1 and RAC1b thro… Co-author DOI 10.3390/cancers13215541↗
  26. Organotypic Slice Cultures as Preclinical Models of Tumor Microenvironment in Primary Pancreatic Cancer and Metastasis. Co-author DOI 10.3791/62541↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ulrich Friedrich Wellner · 20 shared papers, 2021–2026 · strength 3.31
  2. Tobias Keck · 15 shared papers, 2021–2026 · strength 2.43
  3. Hendrik Ungefroren · 11 shared papers, 2021–2025 · strength 2.38
  4. Louisa Bolm · 14 shared papers, 2021–2026 · strength 2.21
  5. Kim C. Honselmann · 14 shared papers, 2021–2026 · strength 2.21
  6. Steffen Deichmann · 10 shared papers, 2021–2026 · strength 1.69
  7. Jens Uwe Marquardt · 7 shared papers, 2022–2026 · strength 1.49
  8. Hryhoriy V. Lapshyn · 9 shared papers, 2021–2026 · strength 1.41
  9. Hendrik Lehnert · 6 shared papers, 2021–2025 · strength 1.15
  10. Benjamin Heckelmann · 4 shared papers, 2023–2026 · strength 1.10
  11. Thaer S. A. Abdalla · 4 shared papers, 2024–2026 · strength 0.75
  12. Christoph Röcken · 3 shared papers, 2026 · strength 0.69
  13. Anna Maxi Wandmacher · 3 shared papers, 2026 · strength 0.69
  14. Annika Bräuer · 3 shared papers, 2026 · strength 0.69
  15. Susanne Sebens · 3 shared papers, 2026 · strength 0.69
  16. Lennart von Fritsch · 3 shared papers, 2024–2026 · strength 0.58
  17. Benedikt Färber · 3 shared papers, 2023–2026 · strength 0.52
  18. Daniela Wesch · 2 shared papers, 2026 · strength 0.47
  19. Anne‐Sophie Mehdorn · 2 shared papers, 2026 · strength 0.47
  20. Natalie Petruch · 3 shared papers, 2021–2024 · strength 0.40
  21. Ekaterina Petrova · 3 shared papers, 2021–2022 · strength 0.35
  22. Richard Ivell · 1 shared paper, 2025 · strength 0.33
  23. Ravinder Anand‐Ivell · 1 shared paper, 2025 · strength 0.33
  24. Oliver Schilling · 2 shared papers, 2021–2023 · strength 0.28
  25. Holger Kalthoff · 1 shared paper, 2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.